Abstract
Liver disease is a major cause of morbidity and mortality among people living with HIV (PLWH). Diagnosis of these co-infections should be a priority in HIV-infected pregnant women so that they can receive appropriate and effective treatment. However, the prevalence of these infections in this vulnerable population remains poorly documented in Côte d'Ivoire. The objective of this study is to assess the seroprevalence of hepatitis B virus (HBV) or hepatitis C virus (HCV) co-infections in HIV-infected pregnant women undergoing ARV treatment in Abidjan (Côte d’Ivoire). A cross-sectional study among HIV-infected pregnant women was conducted from September 2017 to May 2018 in Abidjan. HBV and HCV serological tests were performed with the electrochemiluminescence method "ECLIA" on Cobas E 411. A total of one hundred (n = 100) HIV-infected pregnant women were included. The results showed that 6% (n=6/100) of the HIV-infected pregnant women had positive HBV serology and no HIV-HCV co-infection was detected. Of the 100 HIV-infected pregnant women included in this study, 23% had undergone surgery. In this population, HBsAg was positive in 9% of patients and HCV antibodies were negative in all patients. The data from this study support the implementation of large-scale sentinel surveillance in Côte d'Ivoire in order to refine data on the prevalence and circulation of viral hepatitis B and C in high-risk populations such as pregnant women.
Highlights
Human immunodeficiency virus (HIV), viral hepatitis B virus (HBV), and viral hepatitis C virus (HCV) are the three most common chronic viral infections in the world [1, 2]
A total of 100 HIV-infected pregnant women who were followed or came to CIRBA for biological monitoring of hepatitis B and C were included in this study
All pregnant women included were on Antiretroviral Therapy (ARV) therapy (Table 1)
Summary
Human immunodeficiency virus (HIV), viral hepatitis B virus (HBV), and viral hepatitis C virus (HCV) are the three most common chronic viral infections in the world [1, 2]. According to the World Health Organization (WHO), of the 36.7 million people living with HIV (PLHIV) worldwide, 2.7. Million are chronically infected with HBV and 2.3 million with HCV [3]. Because of the common mode of transmission of these three viruses (blood, sexual and mother-to-child routes, etc.), the number of HIV-HBV or HIV-HCV co-infected persons remains high [4]. According to the WHO, liver disease is a major cause of morbidity and mortality among PLHIV [3]. For HBV, the use of nucleoside reverse transcriptase
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
